生物医药行业的2025新年不是从 1 月 1 日开始的，而是始于人们涌向旧金山。一大波投资人和企业高管们齐聚JP摩根大会，为 2025 年绘制路线图，并评估和交流金融和政治领域的前景。

In pancreatic cancer, pelareorep previously demonstrated a strong efficacy signal when administered with gemcitabine, nab-paclitaxel and atezolizumab. Our new safety data indicate its ability to also ...

GSK’s share price has been pressured recently from several negative events, but this may leave a bargain to be had. I've ...

GSK’s Jemperli is designed to help the body’s immune system find and attack cancer cells, and is already approved in the EU ...

Upcoming patent expirations are driving pharmaceutical companies to acquire in 2025. In Sweden, we may be on our way to ...

Potential antitrust deregulation could foster a more favourable environment for larger M&A deals in 2025, though skepticism ...

While the deals done this week are important for the future direction of the industry – US company Gilead (US:GILD) inked the biggest, paying up to $1.7bn for Leo Pharma’s range of pre-clinical ...

每年如约而至的JPM大会，都堪称制药企业们的大型灯前秀。 在这一场备受关注的盛会上，药企们不仅总结过去一年得与失，更关键的是，借此机会更新一年的战略打法，提升市场预期。

It was an extremely busy week in the biotech sector, with several companies making important presentations at the J.P. Morgan ...

AbbVie and Gilead are going back to their roots and leaning on their established areas of expertise to set themselves up for ...

在全球制药行业的聚光灯下，GSK（葛兰素史克）于2025年筹划重要转型，1月13日在JPM大会上宣布以10亿美元收购生物医药公司IDRx，标志着该公司对抗肿瘤市场的再一次尝试。尽管此交易在制药行业并不算巨大，但展示了GSK在策略上的新思路：相较于同业公司常常进行高达百亿美元的大并购，GSK选择更谨慎的小额收购，以稳步推进其肿瘤药物的研发与市场表现。从近年来的表现来看，GSK在行业中并不突出，随着业 ...

GSK plans five new product approvals by 2025, highlights strong specialty growth, and acquires IDRx for $1 billion to expand its oncology portfolio.